Three Months Ended September 30,

Nine Months Ended September 30,

2025

2024

2025

2024

Net product sales

$

4,283,979

$

2,654,186

$

11,116,279

$

6,941,042

Less:

Cost of goods sold

(101,977

)

(104,024

)

(311,269

)

(238,031

)

Eversana profit sharing

(3,640,048

)

(2,277,308

)

(9,447,180

)

(5,921,230

)

Employee expenses

(619,572

)

(561,258

)

(1,889,466

)

(1,819,230

)

Professional fees

(687,161

)

(546,740

)

(2,319,005

)

(1,674,494

)

Stock-based compensation

(105,056

)

(131,587

)

(293,693

)

(512,194

)

Sales and marketing expenses

(179,003

)

(194,201

)

(540,556

)

(561,293

)

Other operating expenses(1)

(88,850

)

(124,725

)

(313,393

)

(225,009

)

Interest income

107,507

99,294

338,894

226,353

Interest expense (non-cash)

(126,027

)

(126,027

)

(373,973

)

(375,342

)

Total segment costs loss and net loss

$

(1,156,208

)

$

(1,312,390

)

$

(4,033,362

)

$

(4,159,428

)